An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  • End date
    Oct 29, 2026
  • participants needed
  • sponsor
    Merck Sharp & Dohme LLC
Updated on 27 October 2022
systemic therapy
clear cell renal cell carcinoma


The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).

The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.

Condition Carcinoma, Renal Cell
Treatment Pembrolizumab, Lenvatinib, Belzutifan, Pembrolizumab/Quavonlimab
Clinical Study IdentifierNCT04736706
SponsorMerck Sharp & Dohme LLC
Last Modified on27 October 2022


Yes No Not Sure

Inclusion Criteria

Has histologically confirmed diagnosis of RCC with clear cell component
Has received no prior systemic therapy for advanced ccRCC
Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib
Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last
Has adequately controlled blood pressure with or without antihypertensive medications
Has adequate organ function
Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation

Exclusion Criteria

Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
Has had major surgery, other than nephrectomy within 4 weeks prior to randomization
Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
Has received prior radiotherapy within 2 weeks prior to first dose of study intervention
Has hypoxia or requires intermittent supplemental oxygen or requires chronic supplemental oxygen
Has clinically significant cardiac disease within 12 months from first dose of study intervention
Has a history of interstitial lung disease
Has symptomatic pleural effusion; a participant who is clinically stable following treatment of this condition is eligible
Has preexisting gastrointestinal or non-gastrointestinal fistula
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment
Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study
Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed
Has an active autoimmune disease that has required systemic treatment in the past 2 years
Has a history of noninfectious pneumonitis that required steroids or has current pneumonitis
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B
Has radiographic evidence of intratumoral cavitation, encasement or invasion of a major blood vessel
Has clinically significant history of bleeding within 3 months prior to randomization
Has had an allogenic tissue/solid organ transplant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note